Translation
Notice: This document is an excerpt translation of the original Japanese document and is only for reference purposes. In the event of any discrepancy between this translated document and the original Japanese document, the latter shall prevail.
Summary of Consolidated Financial Results | ||
for the Nine Months Ended April 30, 2022 | ||
(Based on Japanese GAAP) | ||
June 3, 2022 | ||
Company name: | Pharma Foods International Co.,Ltd. | |
Stock exchange listing: | Tokyo | |
Stock code: | 2929 | URL https://www.pharmafoods.co.jp |
Representative: | President | Mujo Kim |
Inquiries: | General Manager of Administration | Atsushi Yamatsu | TEL 075-394-8600 |
Department | |||
Scheduled date to file Quarterly Securities Report: | June 14, 2022 | ||
Scheduled date to commence dividend payments: | - | ||
Preparation of supplementary material on quarterly financial results: | Yes | ||
Holding of quarterly financial results meeting: | No |
(Amounts less than one million yen are rounded down)
1. Consolidated financial results for the nine months ended April 30, 2022 (from August 1, 2021 to April 30, 2022)
(1) Consolidated operating results (cumulative) | Percentages indicate year-on-year changes | |||||||||||||||||
Net sales | Operating profit | Ordinary profit | Profit attributable to | |||||||||||||||
owners of parent | ||||||||||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | |||||||||||
Nine months ended April 30, 2022 | 44,050 | 30.5 | 931 | (64.6) | 1,076 | (60.4) | (284) | - | ||||||||||
Nine months ended April 30, 2021 | 33,748 | 203.7 | 2,633 | - | 2,716 | - | 1,553 | - | ||||||||||
Earnings per share | Diluted earnings per share | |||||||||||||||||
Yen | Yen | |||||||||||||||||
Nine months ended April 30, 2022 | (9.80) | - | ||||||||||||||||
Nine months ended April 30, 2021 | 53.49 | 53.46 | ||||||||||||||||
(2) Consolidated financial position | ||||||||||||||||||
Total assets | Net assets | Equity ratio | ||||||||||||||||
Millions of yen | Millions of yen | % | ||||||||||||||||
As of April 30, 2022 | 30,273 | 7,097 | 23.4 | |||||||||||||||
As of July 31, 2021 | 20,944 | 8,465 | 40.4 | |||||||||||||||
2. Cash dividends | ||||||||||||||||||
Annual dividends per share | ||||||||||||||||||
1st quarter-end | 2nd quarter-end | 3rd quarter-end | Fiscal year-end | Total | ||||||||||||||
Yen | Yen | Yen | Yen | Yen | ||||||||||||||
Year ended July 31, 2021 | - | 5.00 | - | 20.00 | 25.00 | |||||||||||||
Year ending July 31, 2022 | - | 10.00 | - | |||||||||||||||
Year ending July 31, 2022 (Forecast) | 10.00 | 20.00 |
3. Forecast of consolidated financial results for the year ending July 31, 2022 (from August 1, 2021 to July 31, 2022)
Percentages indicate year-on-year changes
Net sales | Operating profit | Ordinary profit | Profit attributable to | Earnings per share | ||||||
owners of parent | ||||||||||
Millions of yen | % | Millions of yen | % | Millions of yen | % | Millions of yen | % | Yen | ||
Full year | 60,900 | 30.3 | 3 | (99.9) | 147 | (97.5) | (1,500) | - | (51.71) |
1
4. Notes
- Changes in significant subsidiaries during the nine months ended April 30, 2022 (changes in specified subsidiaries resulting in the change in scope of consolidation):
- Application of special accounting methods for preparing quarterly consolidated financial statements:
No
No
(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
Changes in accounting policies due to revisions to accounting standards and other regulations: | Yes |
Changes in accounting policies due to other reasons: | No |
Changes in accounting estimates: | No |
Restatement of prior period financial statements: | No |
(4) Number of issued shares (common shares)
Total number of issued shares at the end of the period (including treasury shares)
As of April 30, 2022 29,073,800 shares As of July 31, 2021 29,062,100 shares Number of treasury shares at the end of the period
As of April 30, 2022 | 50,053 | shares | As of July 31, 2021 | - | shares | |
Average number of shares during the period (cumulative from the beginning of the fiscal year) | ||||||
Nine months ended April 30, 2022 | 29,002,044 | shares | Nine months ended April 30, 2021 | 29,051,563 | shares |
2
Quarterly consolidated financial statements
Consolidated balance sheets
(Millions of yen) | |||
As of July 31, 2021 | As of April 30, 2022 | ||
Assets | |||
Current assets | |||
Cash and deposits | 9,794 | 9,545 | |
Notes and accounts receivable - trade | 4,920 | 5,946 | |
Electronically recorded monetary claims - operating | - | 567 | |
Merchandise and finished goods | 2,659 | 4,832 | |
Work in process | 54 | 472 | |
Raw materials and supplies | 35 | 628 | |
Other | 473 | 1,173 | |
Allowance for doubtful accounts | (3) | (2) | |
Total current assets | 17,933 | 23,165 | |
Non-current assets | |||
Property, plant and equipment | |||
Buildings and structures, net | 879 | 2,526 | |
Machinery, equipment and vehicles, net | 4 | 393 | |
Tools, furniture and fixtures, net | 178 | 176 | |
Land | 726 | 1,491 | |
Leased assets, net | 20 | 33 | |
Construction in progress | - | 76 | |
Total property, plant and equipment | 1,808 | 4,700 | |
Intangible assets | |||
Goodwill | 140 | 222 | |
Other | 45 | 36 | |
Total intangible assets | 185 | 259 | |
Investments and other assets | |||
Investment securities | 335 | 1,380 | |
Other | 680 | 768 | |
Allowance for doubtful accounts | (0) | (0) | |
Total investments and other assets | 1,016 | 2,149 | |
Total non-current assets | 3,010 | 7,108 | |
Total assets | 20,944 | 30,273 |
3
(Millions of yen) | |||
As of July 31, 2021 | As of April 30, 2022 | ||
Liabilities | |||
Current liabilities | |||
Notes and accounts payable - trade | 846 | 1,169 | |
Short-term borrowings | 2,500 | 13,000 | |
Current portion of long-term borrowings | 939 | 745 | |
Accounts payable - other | 3,283 | 5,677 | |
Income taxes payable | 2,000 | 105 | |
Provision for bonuses | 3 | 168 | |
Other | 1,404 | 808 | |
Total current liabilities | 10,978 | 21,674 | |
Non-current liabilities | |||
Long-term borrowings | 1,458 | 913 | |
Retirement benefit liability | 16 | 435 | |
Other | 24 | 152 | |
Total non-current liabilities | 1,499 | 1,501 | |
Total liabilities | 12,478 | 23,176 | |
Net assets | |||
Shareholders' equity | |||
Share capital | 2,038 | 2,042 | |
Capital surplus | 1,817 | 1,820 | |
Retained earnings | 4,599 | 3,390 | |
Treasury shares | - | (138) | |
Total shareholders' equity | 8,455 | 7,114 | |
Accumulated other comprehensive income | |||
Valuation difference on available-for-sale securities | 8 | (17) | |
Total accumulated other comprehensive income | 8 | (17) | |
Share acquisition rights | 1 | 0 | |
Total net assets | 8,465 | 7,097 | |
Total liabilities and net assets | 20,944 | 30,273 |
4
Consolidated statements of income (cumulative) and consolidated statements of comprehensive income (cumulative)
Consolidated statements of income (cumulative)
(Millions of yen) | |||
Nine months ended | Nine months ended | ||
April 30, 2021 | April 30, 2022 | ||
Net sales | 33,748 | 44,050 | |
Cost of sales | 5,062 | 8,828 | |
Gross profit | 28,685 | 35,222 | |
Selling, general and administrative expenses | |||
Research and development expenses | 354 | 475 | |
Advertising expenses | 19,365 | 26,158 | |
Commission expenses | 1,973 | 2,465 | |
Amortization of goodwill | 32 | 34 | |
Other | 4,327 | 5,156 | |
Total selling, general and administrative expenses | 26,052 | 34,290 | |
Operating profit | 2,633 | 931 | |
Non-operating income | |||
Interest income | 2 | 1 | |
Dividend income | 0 | 24 | |
Foreign exchange gains | 22 | 29 | |
Subsidy income | 34 | 74 | |
Share of profit of entities accounted for using equity method | 9 | 12 | |
Outsourcing service income | 12 | 12 | |
Other | 15 | 21 | |
Total non-operating income | 97 | 175 | |
Non-operating expenses | |||
Interest expenses | 9 | 18 | |
Commission expenses | 5 | 12 | |
Other | 0 | 0 | |
Total non-operating expenses | 14 | 30 | |
Ordinary profit | 2,716 | 1,076 | |
Extraordinary income | |||
Gain on bargain purchase | - | 82 | |
Total extraordinary income | - | 82 | |
Extraordinary losses | |||
Loss on retirement of non-current assets | 0 | 0 | |
Total extraordinary losses | 0 | 0 | |
Profit before income taxes | 2,715 | 1,158 | |
Income taxes | 1,161 | 1,442 | |
Profit (loss) | 1,553 | (284) | |
Profit (loss) attributable to owners of parent | 1,553 | (284) |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Pharma Foods International Co. Ltd. published this content on 06 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 June 2022 06:21:06 UTC.